摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4Z,7R,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxy-4,8,10,12,16,19-docosahexaenoic acid | 1268720-28-0

中文名称
——
中文别名
——
英文名称
(4Z,7R,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxy-4,8,10,12,16,19-docosahexaenoic acid
英文别名
(4Z,7R,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid;7R,14S-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid;7R,14S-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-hexanoic acid;7R,14S-docosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid;maresin 1;maresin-1
(4Z,7R,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxy-4,8,10,12,16,19-docosahexaenoic acid化学式
CAS
1268720-28-0
化学式
C22H32O4
mdl
——
分子量
360.494
InChiKey
HLHYXXBCQOUTGK-FHCQLJOMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    559.4±50.0 °C(Predicted)
  • 密度:
    1.048±0.06 g/cm3(Predicted)
  • 溶解度:
    DMF:50mg/mL; DMSO:50mg/mL;乙醇:50mg/mL; PBS(pH 7.2):0.05 mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    26
  • 可旋转键数:
    14
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    77.8
  • 氢给体数:
    3
  • 氢受体数:
    4

制备方法与用途

生物活性 Maresin 1 是人体内源性产生的 DHA 特异性调节介质,可以刺激胞内 Ca2+ 的产生和分泌,并具有抗炎活性。

体外研究 Maresin 1 (MaR1, 浓度为 300 nM) 可以减少中性粒细胞的迁移和活性氧物种的生成,同时降低 IL-1β、TNF-α、IL-6 和 INF-γ 的产生。具体实验如下:

  • 细胞存活率测定
    • 细胞系:中性粒细胞(2 ×10^5 cells/well)
    • 浓度:300 nM
    • 培养时间:30 min
    • 结果:将 LPS (1 mg/ml) 存在或不存在 MaR1 (300 nM) 的条件培养24小时,观察到贴壁细胞的反应(参考 [3])

体内研究 Maresin 1 (MaR1) 剂量依赖性地抑制神经元中的 TRPV1 现象,阻止辣椒素 (100 nM)-诱导的内向电流(IC50 = 0.49 nM),并减少小鼠炎症和化疗引起的神经病理性疼痛。具体实验如下:

  • MaR1 (0.1, 0.3, 和 1 μg/动物,腹腔注射) 可保护小鼠免受急性 DSS 引起的结肠炎。
  • MaR1 (0.3 和 1 μg/动物,腹腔注射) 处理显著减少急性 DSS 引起的结肠炎中的宏观损伤。

实验数据:

  • 动物模型:8-10 周龄雄性 CD1 小鼠(通过 DSS 引发炎症)
  • 剂量:0.1, 0.3, 和 1 μg/动物
  • 给药途径:每天一次,连续 7 天从第 0 天开始
  • 结果:MaR1 (0.3 和 1 mg/动物) 显著降低小鼠结肠组织中的 MPO 平。

反应信息

点击查看最新优质反应信息

文献信息

  • Stereoselective synthesis of maresin 1
    作者:Jørn E. Tungen、Marius Aursnes、Trond Vidar Hansen
    DOI:10.1016/j.tetlet.2015.02.080
    日期:2015.4
    Maresin 1 is a potent anti-inflammatory and pro-resolving lipid mediator derived from docosahexaenoic acid. The total synthesis of maresin 1 is achieved in 10 steps and in 7% overall yield. The Evans–Nagao aldol reaction between (2E,4E)-5-bromopenta-2,4-dienal and different chiral auxiliaries is investigated. The reported synthesis is efficient and highly stereoselective, affording multi-milligram
    Maresin 1是衍生自二十二碳六烯酸的有效消炎和促分解脂质介质。Maresin 1的总合成可通过10个步骤完成,总产率为7%。研究了(2 E,4 E)-5-戊达2,4-二烯醛与不同手性助剂之间的Evans–Nagao羟醛反应。报道的合成是有效的和高度立体选择性的,提供了数毫克量的这种生物学上有趣的脂质介体。
  • Compounds and methods for modulating vascular injury
    申请人:The Regents of the University of California
    公开号:US10111847B2
    公开(公告)日:2018-10-30
    Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that fmd use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions fmd use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g., restenosis), and applications related to chronic inflammatory diseases of the vascular wall.
    本发明提供了调节受试者血管损伤和/或血管瘢痕愈合反应的方法。因此,本公开的各个方面涉及使用促溶解脂质介质来调节血管壁的炎症和/或再狭窄。本公开的另一方面涉及使用促溶解脂质介质调节血管平滑肌细胞(VSMC)或血管内皮细胞(VEC)的生物活性。可用于上述方法的促溶解脂质介质包括欧米伽-3 多不饱和脂肪酸和欧米伽-6 多不饱和脂肪酸的衍生物,如 resolvins、protectins、lipoxins 和 maresins 及其治疗上稳定的类似物。此外,还提供了用于上述方法的血管装置和组合物。这些方法、装置和组合物可用于多种应用,包括与治疗血管损伤和血管瘢痕(如再狭窄)有关的应用,以及与血管壁慢性炎症性疾病有关的应用。
  • Oils with anti-inflammatory activity containing natural Specialized Proresolving Mediators and their precursors
    申请人:Solutex NA LLC
    公开号:US11077083B2
    公开(公告)日:2021-08-03
    The present invention encompasses oils that have anti-inflammatory or resolution-stimulating activity that contain or are enriched with Specialized Proresolving Mediators (SPM) or SPM precursors, which originate from an oil obtained from organisms containing long chain omega-3 polyunsaturated fatty acids, such as fish, crustaceae, algae, and mollusks. The invention also encompasses a method for the production of these oils, and the utilization of the oils for nutritional supplements, pharmaceutical formulations, and cosmetic formulations, which can be employed for treating an inflammatory condition.
    本发明包括具有抗炎或刺激溶解活性的油类,这些油类含有或富含特化促溶解介质(SPM)或 SPM 前体,这些特化促溶解介质或 SPM 前体来源于从含有长链欧米加-3 多不饱和脂肪酸生物(如鱼类、甲壳类、藻类和软体动物)中获得的油类。本发明还包括生产这些油的方法,以及将这些油用于营养补充剂、药物制剂和化妆品制剂的方法,这些制剂可用于治疗炎症。
  • Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
    申请人:Solutex NA LLC
    公开号:US11077084B2
    公开(公告)日:2021-08-03
    The present invention encompasses oils that have anti-inflammatory or resolution-stimulating activity that contain or are enriched with Specialized Proresolving Mediators (SPM) or SPM precursors, which originate from an oil obtained from organisms containing long chain omega-3 polyunsaturated fatty acids, such as fish, crustaceae, algae, and mollusks. The invention also encompasses a method for the production of these oils, and the utilization of the oils for nutritional supplements, pharmaceutical formulations, and cosmetic formulations, which can be employed for treating an inflammatory condition.
    本发明包括具有抗炎或刺激溶解活性的油类,这些油类含有或富含特化促溶解介质(SPM)或 SPM 前体,这些特化促溶解介质或 SPM 前体来源于从含有长链欧米加-3 多不饱和脂肪酸生物(如鱼类、甲壳类、藻类和软体动物)中获得的油类。本发明还包括生产这些油的方法,以及将这些油用于营养补充剂、药物制剂和化妆品制剂的方法,这些制剂可用于治疗炎症。
  • Cysteinyl-proresolving mediators that promote resolution of infection and organ protection
    申请人:THE BRIGHAM AND WOMEN'S HOSPITAL
    公开号:US11135228B2
    公开(公告)日:2021-10-05
    A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristics of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have an oxylipin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow/reperfusion damage.
    本研究揭示了在自溶性炎性渗出物中发现的一系列生物活性化合物。这些化合物的紫外发色团具有共轭三烯双键系统的特征,并与三烯的烯丙基辅助色素相耦合。对这些化合物的进一步阐释表明,它们具有通过辅助色素与肽或氨基酸分子共轭的氧化脂素骨架。在某些实施方案中,辅助色素是。这些化合物在体外和体内具有强大的生物活性,包括促进感染的解决,刺激巨噬细胞吞噬细菌;保护组织免受中性粒细胞介导的损伤,促进组织修复和再生,防止或限制第二器官回流/再灌注损伤。
查看更多